{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:28:15Z","timestamp":1782905295639,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004884","name":"Education Department of Sichuan Province","doi-asserted-by":"publisher","award":["SCYG2020\u201004"],"award-info":[{"award-number":["SCYG2020\u201004"]}],"id":[{"id":"10.13039\/501100004884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004884","name":"Education Department of Sichuan Province","doi-asserted-by":"publisher","award":["SCYG2019\u201004"],"award-info":[{"award-number":["SCYG2019\u201004"]}],"id":[{"id":"10.13039\/501100004884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre\u2010exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection. However, due to social, psychological and other reasons, the compliance with daily oral TDF\u2010FTC in real life is low. Long\u2010acting cabotegravir is currently the only long\u2010acting drug approved by the U.S. Food and Drug Administration (FDA) for HIV PrEP. Due to the long dosing interval (8\u00a0weeks), long\u2010acting cabotegravir has low compliance requirements for people at high risk of HIV infection. We aimed to discuss the feasibility of long\u2010acting cabotegravir to replace TDF\u2010FTC as HIV PrEP based on efficacy and safety analyses. Randomized controlled trials were retrieved, and R software was used for meta\u2010analysis after data extraction. and discussion: Results of the meta\u2010analysis showed that compared with TDF\u2010FTC, long\u2010acting cabotegravir was associated with a lower risk of HIV infection (HR\u00a0=\u00a00.22, 95% CI: 0.08\u20130.59, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.01), less decreased creatinine clearance (RR\u00a0=\u00a00.96, 95% CI: 0.93\u20130.99, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.01), but more tolerated injection sites adverse events (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.01). No statistically significant differences were found between long\u2010acting cabotegravir and oral placebo in non\u2010injection\u2010related adverse events (creatine phosphokinase, headache, nasopharyngitis, upper respiratory tract infection and gastroenteritis) (<jats:italic>p<\/jats:italic>\u00a0&gt;\u00a00.05). Long\u2010acting cabotegravir has a manageable safety profile and is more effective than TDF\u2010FTC in preventing HIV infection. Interestingly, decreased creatinine clearance occurred less frequently with long\u2010acting cabotegravir than with TDF\u2010FTC. Long\u2010acting cabotegravir is very promising to replace TDF\u2010TFC in the future, which requires more large\u2010sample, high\u2010quality RCTs to verify.<\/jats:p>","DOI":"10.1002\/rmv.2460","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T03:40:16Z","timestamp":1684381216000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of long\u2010acting cabotegravir versus oral tenofovir disoproxil fumarate\u2010emtricitabine as HIV pre\u2010exposure prophylaxis: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-4049","authenticated-orcid":false,"given":"Xiu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy The Affiliated Hospital of Southwest Medical University  Luzhou China"},{"name":"School of Pharmacy Southwest Medical University  Luzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine The Affiliated Hospital of Southwest Medical University  Luzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiu","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Affiliated Hospital of Southwest Medical University  Luzhou China"},{"name":"School of Pharmacy Southwest Medical University  Luzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Affiliated Hospital of Southwest Medical University  Luzhou China"},{"name":"School of Pharmacy Southwest Medical University  Luzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqing","family":"Wei","sequence":"additional","affiliation":[{"name":"Luzhou Center for Disease Control and Prevention  Luzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Affiliated Hospital of Southwest Medical University  Luzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization.Global HIV & AIDS Statistics. Accessed 15 June 2022.https:\/\/www.unaids.org\/en\/resources\/fact\u2010sheet"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6989717"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000001858"},{"key":"e_1_2_10_5_1","unstructured":"KeyUNAIDS.Populations Atlas. Accessed 17 June 2022.http:\/\/www.aidsinfoonline.org\/kpatlas\/document\/kp_data_sources.pdf"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd013207.pub2"},{"key":"e_1_2_10_7_1","unstructured":"World Health Organization.Consolidated Guidelines on HIV Prevention Testing Treatment Service Delivery and Monitoring: Recommendations for a Public Health Approach;2021. Accessed 18\u00a0June 2022.https:\/\/www.who.int\/publications\/i\/item\/9789240031593"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1011205"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1108524"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(13)61127\u20107"},{"key":"e_1_2_10_11_1","unstructured":"Centers for Disease Control and Prevention; US Public Health Service.Preexposure Prophylaxis for the Prevention of HIV Infection in the United States\u20102014: A Clinical Practice Guideline;2014."},{"key":"e_1_2_10_12_1","unstructured":"European AIDS Clinical Society (EACS).Guidelines Version 8.1;2016."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1202614"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25298"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25463"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/coh.0000000000000002"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10096"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106343"},{"key":"e_1_2_10_19_1","unstructured":"National Institutes of Health (NIH).NIH Celebrates FDA Approval of Long\u2010Acting Injectable Drug for HIV Prevention. Accessed 17 June 2022.https:\/\/www.nih.gov\/news\u2010events\/news\u2010releases\/nih\u2010celebrates\u2010fda\u2010approval\u2010long\u2010acting\u2010injectable\u2010drug\u2010hiv\u2010prevention"},{"key":"e_1_2_10_20_1","unstructured":"MurrayM.FDA Approves Cabenuva First Injectable Antiretroviral for HIV. Accessed 17 June 2022.https:\/\/www.goodrx.com\/blog\/cabenuva\u2010injectable\u2010hiv\u2010antiretroviral\u2010almost\u2010here\/"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103018(16)30113\u20108"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114700"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(22)00538\u20104"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2101016"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002690"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103018(17)30068\u20101"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001343"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000000469"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248707"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1511346"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2009.14"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0b013e3181a666eb"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.318"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103018(16)30153\u20109"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000000906"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000001566"},{"key":"e_1_2_10_37_1","unstructured":"Pre\u2010Exposure Prophylaxis for the Prevention of HIV Infection in the United States\u20102021 Update: A Clinical Practice Guideline.https:\/\/www.cdc.gov\/hiv\/guidelines\/preventing.html. Accessed 17 June 2022."},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.7326\/m21\u20101548"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0420"},{"key":"e_1_2_10_40_1","unstructured":"UNAIDS.Track Commitments to End AIDS by 2030. Accessed June 18 2022.https:\/\/www.unaids.org\/en\/resources\/documents\/2016\/fast\u2010track\u2010commitments"}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.2460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:17:18Z","timestamp":1692289038000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.2460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/rmv.2460"],"URL":"https:\/\/doi.org\/10.1002\/rmv.2460","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"value":"1052-9276","type":"print"},{"value":"1099-1654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"2022-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2460"}}